Differences in the incidences of the main breast cancer types (Luminal A, Luminal B, HER2-overexpressed and the triple-negative tumors) between DCIS and invasive ductal cancers (IDC) were used to calculate the relative rate of progression from the in situ stage to invasive form. Here, ERBB2 is linked to ductal breast carcinoma in situ.